Wockhardt charting a recovery riding on a promising new antibiotic

While global trials are on, doctors have started using one of company's antibiotics against superbugs to save lives

Mumbai-headquartered Wockhardt is charting a turnaround plan, riding on its promising antibiotic pipeline, led by a candidate codenamed WCK5222.

Rarely, an undertrial novel drug developed in India is sought after by doctors to save patient lives. WCK5222 has already saved five patients here under a compassionate use programme.

WCK5222 — Cefepime-Zidebactam — is an injectable novel combination antibiotic that has been granted qualified infectious disease product (QIDP) status by the US Food and Drug Administration (USFDA). It targets several critical and high-priority superbugs listed by the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC) and the